EUCTR2010-020881-53-NL
Active, not recruiting
Not Applicable
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn’s Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Crohns Disease
- Sponsor
- Amgen Inc
- Enrollment
- 195
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject was randomized into study 20090072 and completed the week 12 evaluation.
- •Subject completed the week 12 evaluation in study 20090072 no more than 1 year prior to the planned first visit of AMG 827 in 20100008\.
- •Subject or subject’s legally acceptable representative has provided informed consent.
- •Subject meets regional recommendations for immunizations, eg, United States Centers for Disease Control and Prevention recommendations for subjects enrolled in the United States.
- •For subjects with \= 3 months between the week 12 visit of 20090072 and the planned first dose of AMG 827 in 20100008: If testing is clinically indicated in the opinion of the investigator (eg, because of known recent exposure), then subject has negative test for hepatitis B, hepatitis C, and/or human immunodeficiency virus (HIV).
- •For female subjects with \= 4 weeks between the week 12 visit of 20090072 and the planned first dose of AMG 827 in 20100008: Subject has a negative urine pregnancy test at baseline prior to the first dose of AMG 827 in the open\-label extension (except those at least 2 years post menopausal or surgically sterile).
- •For female subjects with \> 4 weeks between the week 12 visit of 20090072 and the planned first dose of AMG 827 in 20100008: Subject has a negative serum pregnancy test within 28 days before initiating AMG 827 and a negative urine pregnancy test at baseline prior to the first dose of AMG 827 in the open\-label extension (except those at least 2 years post menopausal or surgically sterile).
- •For subjects with \= 3 months between the week 12 visit of 20090072 and the planned first dose of AMG 827 in 20100008, if clinically indicated in the opinion of the investigator (eg, because of known recent exposure):
- •\- If the subject entered 20090072 with a negative purified protein derivative (PPD) test: Subject must have a negative PPD test within 30 days prior to the planned first dose of AMG 827\. Tuberculin skin tests should be considered positive when they have greater than or equal to 5 mm of induration at 48\-72 hours after test is placed.
- •\- If the subject entered 20090072 with a positive PPD: Subject must have a negative Quantiferon test within 30 days prior to the planned first dose of AMG 827\.
Exclusion Criteria
- •AMG 827 specific criteria
- •Subject had any serious adverse event reported during study 20090072 and considered to be related to investigational product.
- •Subject experienced an adverse event or laboratory abnormality in study 20090072 that, in the opinion of the investigator, could cause extension of treatment to be detrimental to the subject, prevent the subject from completing the study, or interfere with the interpretation of the study results.
- •Subject has known sensitivity to any of the products to be administered during dosing.
- •Other medical conditions
- •Subject is currently experiencing an infection of Common Terminology Criteria for Adverse Events grade 2 (if requiring oral medication) or higher. Subject is ineligible until the infection resolves.
- •Subject has a serious infection, defined as requiring hospitalization or intravenous antibiotics, within 8 weeks before the first dose of AMG 827 in 20100008\.
- •For subjects with \= 3 months between the week 12 visit of 20090072 and the planned first dose of AMG 827 in 20100008: Subject has recurrent or chronic infections, defined as \= 3 infections requiring anti\-microbials over the past 12 months prior to screening.
- •Subject has a significant concurrent medical condition, including
- •\- Type 1 diabetes
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's DiseaseNL-OMON36733Amgen25
Active, not recruiting
Phase 1
Safety Study in Subjects With Crohn's DiseaseCrohn's DiseaseMedDRA version: 14.0Level: LLTClassification code 10013099Term: Disease CrohnsSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2010-020881-53-BEAmgen Inc195
Completed
Not Applicable
Evaluation of long-term safety and efficacy after neuroprotective gene therapy with SIV-hPEDF for retinitis pigmentosaRetinitis PigmentosaJPRN-UMIN000049825Kyushu University10
Active, not recruiting
Not Applicable
A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Rheumatoid Arthritis.EUCTR2009-016119-38-PLAmgen Inc220
Active, not recruiting
Not Applicable
Safety and Efficacy of AMG 827 in Subjects With RARheumatoid arthritisMedDRA version: 13.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2009-016119-38-GBAmgen Inc220